Organization
Augurex Life Sciences Corp, North Vancouver, Canada
10 abstracts
Abstract
14-3-3 ETA IS AN EARLY RA BIOMARKER THAT IS MODIFIABLE WITH STANDARD DMARDS AND CORRESPONDS WITH IMPROVEMENT IN CLINICAL VARIABLES Org: Jan van Breemen Research Institute, Reade, Netherlands, Univeristy of Alberta, Edmonton, Augurex Life Sciences Corp, North Vancouver, Canada,
Abstract
14-3-3 ETA IS AN INDEPENDENT MARKER OF JOINT DAMAGE THAT COMPLEMENTS CRP AND ANTI-CCP Org: GlaxoSmithKline, Augurex Life Sciences Corp, North Vancouver, Canada,
Abstract
14-3-3 ETA MARKS RADIOGRAPHIC PROGRESSION IN AN EARLY ARTHRITIS COHORT Org: Jan van Breemen Research Institute, Reade, Netherlands, Augurex Life Sciences Corp, North Vancouver, Canada, University of Alberta, Edmonton, Canada,
Abstract
14-3-3 ETA SERO-POSITIVITY MARKS MORE SEVERE DISEASE AND TITRES INFORM RESPONSE TO THERAPY, ALSO IN PATIENTS WITH LOWER CRP Org: Hospital for Special Surgery, New York, United States, VU University Medical Center, Amsterdam, Netherlands, Academic Medical Center, Amsterdam, AMC/ University of Amsterdam, Amsterdam, Netherlands, Rheumatology Patient Foundation, Cocoa, United States,
Abstract
14-3-3ETA AS A NOVEL RA DRUG TARGET: ANTI-14-3-3ETA MONOCLONAL ANTIBODY DELAYS THE ONSET AND MITIGATES THE SEVERITY OF ARTHRITIS IN CIA MICE Org: National Research Council, Ottawa, Augurex Life Sciences Corp, North Vancouver, Canada, University of Alberta, Edmonton, Canada,
Abstract
14-3-3ETA CLINICAL ASSAYS ARE EQUIVALENT AND RF DOES NOT INTERFERE WITH ITS QUANTITATION Org: Quest Diagnostics LLC, Augurex Life Sciences Corp, North Vancouver, Canada, U of Alberta, Edmonton,
Abstract
14-3-3ETA IS AN INDEPENDENT PREDICTOR OF RADIOGRAPHIC CHANGES IN EARLY RA AND HIGHER TITRES INFORM A HIGHER LIKELIHOOD OF JOINT DAMAGE PROGRESSION Org: Reade Rheumatology Research Institute, University of Alberta, VU University Medical Center, Augurex Life Sciences Corp, North Vancouver, Canada,
Abstract
14-3-3ETA PREDICTS JOINT DAMAGE PROGRESSION AND FLARING AFTER ADALIMUMAB DISCONTINUATION Org: Hiroshima University Hospital, University of Occupational and Environmental Health, Kitakyushu, Japan, Augurex Life Sciences Corp, North Vancouver, Canada,
Abstract
AUTO-ANTIBODIES TO PAN AND CITRULLINATED 14-3-3 ETA ARE EXPRESSED IN ANTI-CCP NEGATIVE RA Org: University of Alberta, Edmonton, Canada, Hospital for Special Surgery, New York, United States of America, Leiden University, Leiden, Netherlands, Academic Medical Center, Amsterdam, Netherlands, Augurex Life Sciences Corp, North Vancouver, Canada,
Abstract
BASELINE SERUM 14-3-3 ETA LEVELS PREDICT ACR50 RESPONSE TO ADALIMUMAB THERAPY IN PSORIATIC ARTHRITIS Org: Augurex Life Sciences Corp, North Vancouver, Canada, Division of Clinical Immunology/Rheumatology, University of Amsterdam, University of Alberta, GlaxoSmithKline,